JP2013542267A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013542267A5 JP2013542267A5 JP2013539003A JP2013539003A JP2013542267A5 JP 2013542267 A5 JP2013542267 A5 JP 2013542267A5 JP 2013539003 A JP2013539003 A JP 2013539003A JP 2013539003 A JP2013539003 A JP 2013539003A JP 2013542267 A5 JP2013542267 A5 JP 2013542267A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- aliphatic
- compound according
- substituted
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 131
- 125000001424 substituent group Chemical group 0.000 claims description 44
- 208000010877 cognitive disease Diseases 0.000 claims description 28
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 27
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 26
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 208000028698 Cognitive impairment Diseases 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- -1 1,2-methylenedioxy Chemical group 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 claims description 12
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 12
- 125000004429 atom Chemical group 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 208000015114 central nervous system disease Diseases 0.000 claims description 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 8
- MZAGXDHQGXUDDX-JSRXJHBZSA-N (e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/C(N)=O MZAGXDHQGXUDDX-JSRXJHBZSA-N 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 125000001931 aliphatic group Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 8
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 8
- 206010012289 Dementia Diseases 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 210000003169 central nervous system Anatomy 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 230000007000 age related cognitive decline Effects 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 2
- 201000002832 Lewy body dementia Diseases 0.000 claims description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 206010027175 memory impairment Diseases 0.000 claims description 2
- 238000011275 oncology therapy Methods 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 11
- 150000007824 aliphatic compounds Chemical class 0.000 claims 3
- 238000000034 method Methods 0.000 description 12
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 0 Bc1c(*)nnc(*)c1C(O)=O Chemical compound Bc1c(*)nnc(*)c1C(O)=O 0.000 description 1
- DYJNGHZAXRFAJZ-UHFFFAOYSA-N Cc1n[o]c(-c(c(-c2ccccc2)nnc2)c2-c2cccc(C#N)c2)n1 Chemical compound Cc1n[o]c(-c(c(-c2ccccc2)nnc2)c2-c2cccc(C#N)c2)n1 DYJNGHZAXRFAJZ-UHFFFAOYSA-N 0.000 description 1
- MGFXJIWEVFFSHA-UHFFFAOYSA-N NC(c(c(-c1ccccc1)nnc1)c1-c1ccccc1)=O Chemical compound NC(c(c(-c1ccccc1)nnc1)c1-c1ccccc1)=O MGFXJIWEVFFSHA-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41397110P | 2010-11-15 | 2010-11-15 | |
| US61/413,971 | 2010-11-15 | ||
| PCT/US2011/060854 WO2012068161A1 (en) | 2010-11-15 | 2011-11-15 | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013542267A JP2013542267A (ja) | 2013-11-21 |
| JP2013542267A5 true JP2013542267A5 (enExample) | 2015-01-08 |
| JP5916746B2 JP5916746B2 (ja) | 2016-05-11 |
Family
ID=46084380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013539003A Active JP5916746B2 (ja) | 2010-11-15 | 2011-11-15 | 認知障害を処置するためのピリダジン誘導体、組成物、および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9145372B2 (enExample) |
| EP (2) | EP2640391B1 (enExample) |
| JP (1) | JP5916746B2 (enExample) |
| CN (1) | CN103313712B (enExample) |
| AU (1) | AU2011328993B2 (enExample) |
| BR (1) | BR112013012062B1 (enExample) |
| CA (1) | CA2818025A1 (enExample) |
| DK (2) | DK3034079T3 (enExample) |
| EA (1) | EA027840B1 (enExample) |
| MX (2) | MX346185B (enExample) |
| NO (1) | NO3034079T3 (enExample) |
| WO (1) | WO2012068161A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011328993B2 (en) | 2010-11-15 | 2017-03-02 | Agenebio, Inc. | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
| EP2642919A4 (en) * | 2010-11-26 | 2014-10-08 | Brigham & Womens Hospital | METHOD FOR THE INVESTIGATION OF REPEATED HEAD BREAKDOWN THROUGH TWO-DIMENSIONAL MAGNETIC RESONANCE SPECTROSCOPY |
| EP2897963A4 (en) | 2012-09-21 | 2016-03-30 | Uwm Res Foundation Inc | Novel GABAA AGONISTS AND METHOD FOR USE TO COMBAT AIRWAY HYPER REAGIBILITY AND IGNITIONS IN ASTHMA |
| WO2014078377A1 (en) * | 2012-11-14 | 2014-05-22 | Agenebio, Inc. | Methods and compositions for treating schizophrenia |
| NZ760341A (en) | 2013-12-20 | 2021-12-24 | Agenebio Inc | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CA2990004C (en) | 2015-06-19 | 2024-04-23 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| TWI697485B (zh) * | 2015-07-21 | 2020-07-01 | 日商捷恩智股份有限公司 | 含唑啉環的化合物、含有其的電子輸送/注入層用材料、使用其的有機電致發光元件、顯示裝置及照明裝置 |
| BR112019012821A2 (pt) | 2016-12-19 | 2019-11-26 | Agenebio, Inc. | derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo |
| CA3104478A1 (en) | 2018-06-19 | 2019-12-26 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US11862337B2 (en) | 2019-03-19 | 2024-01-02 | Cambridge Cognition Limited | Method and uses of diagnosing and recommending treatment for a psychotic disorder |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| NL7305644A (enExample) | 1972-04-20 | 1973-10-23 | ||
| NL7605526A (nl) | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
| JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US4816456A (en) | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
| NL195004C (nl) | 1987-03-04 | 2003-11-04 | Novartis Ag | Fenylcarbamaat bevattend farmaceutisch preparaat. |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| CA2000786C (en) | 1988-11-07 | 1999-01-26 | Cornelus G. M. Janssen | 3-piperidinyl-1,2-benzisoxazoles |
| US5043345A (en) | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
| DE58905637D1 (de) | 1989-04-14 | 1993-10-21 | Merz & Co Gmbh & Co | Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie. |
| DE69021645T2 (de) | 1989-05-19 | 1996-02-22 | Hoechst-Roussel Pharmaceuticals Inc., Somerville, N.J. | N-(aryloxyalkyl)heteroarylpiperidine und -heteroarylpiperazine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente. |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| JP2807577B2 (ja) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
| JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
| ES2131506T3 (es) | 1990-09-21 | 1999-08-01 | Rohm & Haas | Dihidropiridacinonas y piridacinonas como fungicidas. |
| US5190951A (en) | 1990-10-19 | 1993-03-02 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| WO1992020682A1 (en) | 1991-05-24 | 1992-11-26 | E.I. Du Pont De Nemours And Company | Arthropodicidal anilides |
| US5106856A (en) | 1991-06-07 | 1992-04-21 | Hoechst-Roussel Pharmaceuticals Inc. | [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds |
| TW201311B (enExample) | 1991-06-17 | 1993-03-01 | Hoffmann La Roche | |
| US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| ES2118584T3 (es) | 1994-03-02 | 1998-09-16 | Akzo Nobel Nv | Composicion farmaceutica sublingual o bucal. |
| US6479523B1 (en) | 1997-08-26 | 2002-11-12 | Emory University | Pharmacologic drug combination in vagal-induced asystole |
| WO1999025353A1 (en) | 1997-11-13 | 1999-05-27 | Merck Sharp & Dohme Limited | Therapeutic uses of triazolo-pyridazine derivatives |
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| US6294583B1 (en) | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| WO2000027849A2 (en) | 1998-11-12 | 2000-05-18 | Merck & Co., Inc. | Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same |
| ATE277011T1 (de) | 1999-03-03 | 2004-10-15 | Eisai Co Ltd | Flouride von 4-substituierten piperidin-derivaten |
| GB9911802D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911803D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911804D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9929569D0 (en) | 1999-12-14 | 2000-02-09 | Merck Sharp & Dohme | Therapeutic agents |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US20020151591A1 (en) | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
| TWI239333B (en) | 2000-11-16 | 2005-09-11 | Hoffmann La Roche | Benzodiazepine derivatives as GABA A receptor modulators |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| EA200300854A1 (ru) | 2001-03-01 | 2004-02-26 | Пфайзер Продактс Инк. | Применение обратных агонистов гамка в комбинации с частичными агонистами никотиновых рецепторов, эстрогеном, избирательными модуляторами эстрогена или витамином е для лечения познавательных расстройств |
| WO2003025122A2 (en) | 2001-08-13 | 2003-03-27 | University Of Kentucky Research Foundation | Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment |
| CA2473536A1 (en) | 2002-01-16 | 2003-07-31 | Endo Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating disorders of the central nervous system |
| GB0218876D0 (en) | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
| AU2003246979B8 (en) * | 2002-08-13 | 2009-08-06 | Merck Sharp & Dohme Limited | Phenylpyridazine derivatives as ligands for GABA receptors |
| US7635709B2 (en) | 2002-09-26 | 2009-12-22 | The United States Of America As Represented By The Department Of Veterans Affairs | Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction |
| EP1556019A2 (en) | 2002-10-24 | 2005-07-27 | Merz Pharma GmbH & Co. KGaA | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| CA2589836A1 (en) | 2002-11-22 | 2004-06-10 | The Johns Hopkins University | Target for therapy of cognitive impairment |
| CN1870984A (zh) | 2003-10-22 | 2006-11-29 | 莫茨药物股份两合公司 | 1－氨基环己烷衍生物用于调节淀粉样病变中原纤维生成Aβ肽的沉积的用途 |
| US20060079582A1 (en) | 2004-09-23 | 2006-04-13 | Jeffrey Jonas | Memantine for the treatment of childhood behavioral disorders |
| DE602005008633D1 (de) | 2004-10-12 | 2008-09-11 | Hoffmann La Roche | Imidazoä1,5aütriazoloä1,5dübenzodiazepin-derivative zur behandlung kognitiver störungen |
| CA2584259C (en) | 2004-10-20 | 2013-04-02 | F. Hoffmann-La Roche Ag | Imidazo-benzodiazepine derivatives |
| US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| CA2607226A1 (en) | 2005-05-16 | 2007-02-15 | Wisys Technology Foundation, Inc. | Gabaergic agents to treat memory deficits |
| US8510055B2 (en) | 2005-08-03 | 2013-08-13 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| EP1924712B1 (en) | 2005-08-03 | 2018-10-03 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| US8486979B2 (en) * | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| US7943619B2 (en) * | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| EP2318005B1 (en) | 2008-08-01 | 2017-11-01 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
| WO2010036553A1 (en) * | 2008-09-24 | 2010-04-01 | E. I. Du Pont De Nemours And Company | Fungicidal pyridazines |
| MX2011002915A (es) | 2008-09-25 | 2011-04-21 | Vive Nano Inc | Metodos para producir nanoparticulas polimericas y formulaciones de ingredientes activos. |
| WO2010120370A2 (en) | 2009-04-17 | 2010-10-21 | Xenoport, Inc. | Gamma-amino-butyric acid derivatives as gabab receptor ligands |
| CA2786716A1 (en) | 2010-01-11 | 2011-07-14 | Mithridion, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| WO2012068149A1 (en) | 2010-11-15 | 2012-05-24 | Agenebio, Inc. | Benzodiazepine derivatives, compositions and methods for treating cognitive impairment |
| AU2011328993B2 (en) | 2010-11-15 | 2017-03-02 | Agenebio, Inc. | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
| WO2012161133A1 (ja) * | 2011-05-20 | 2012-11-29 | 日産化学工業株式会社 | 置換ピリダジン化合物及び農園芸用殺菌剤 |
| CA2884566A1 (en) | 2012-09-10 | 2014-03-13 | Matthew R. Lewin | Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade |
| NZ760341A (en) | 2013-12-20 | 2021-12-24 | Agenebio Inc | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
-
2011
- 2011-11-15 AU AU2011328993A patent/AU2011328993B2/en not_active Ceased
- 2011-11-15 EP EP11841746.8A patent/EP2640391B1/en active Active
- 2011-11-15 EP EP15187794.1A patent/EP3034079B1/en active Active
- 2011-11-15 BR BR112013012062-2A patent/BR112013012062B1/pt not_active IP Right Cessation
- 2011-11-15 NO NO15187794A patent/NO3034079T3/no unknown
- 2011-11-15 DK DK15187794.1T patent/DK3034079T3/en active
- 2011-11-15 JP JP2013539003A patent/JP5916746B2/ja active Active
- 2011-11-15 MX MX2013005442A patent/MX346185B/es active IP Right Grant
- 2011-11-15 CN CN201180063261.2A patent/CN103313712B/zh not_active Expired - Fee Related
- 2011-11-15 CA CA2818025A patent/CA2818025A1/en not_active Abandoned
- 2011-11-15 DK DK11841746.8T patent/DK2640391T3/da active
- 2011-11-15 MX MX2017003111A patent/MX383953B/es unknown
- 2011-11-15 US US13/885,569 patent/US9145372B2/en not_active Expired - Fee Related
- 2011-11-15 EA EA201390712A patent/EA027840B1/ru not_active IP Right Cessation
- 2011-11-15 WO PCT/US2011/060854 patent/WO2012068161A1/en not_active Ceased
-
2015
- 2015-09-18 US US14/858,959 patent/US9801879B2/en not_active Expired - Fee Related